Berenberg Bank reissued their buy rating on shares of Life Science REIT (LON:LABS – Free Report) in a report published on Thursday, Marketbeat reports. They currently have a GBX 57 ($0.76) price objective on the stock.
Several other brokerages have also commented on LABS. Shore Capital restated a buy rating on shares of Life Science REIT in a research note on Thursday, September 26th. Jefferies Financial Group lowered their target price on shares of Life Science REIT from GBX 45 ($0.60) to GBX 36 ($0.48) and set a hold rating on the stock in a research report on Friday, August 30th.
View Our Latest Report on Life Science REIT
Life Science REIT Stock Performance
Life Science REIT Dividend Announcement
The business also recently declared a dividend, which will be paid on Thursday, October 31st. Shareholders of record on Thursday, October 3rd will be issued a dividend of GBX 1 ($0.01) per share. The ex-dividend date of this dividend is Thursday, October 3rd. This represents a yield of 3.11%. Life Science REIT’s dividend payout ratio (DPR) is presently -3,333.33%.
See Also
- Five stocks we like better than Life Science REIT
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- Beat the Volatility: Top 3 Low-Beta Stocks to Watch
- What Is WallStreetBets and What Stocks Are They Targeting?
- Visa and Mastercard: Top Payment Stocks to Watch After Rate Cuts
- Canadian Penny Stocks: Can They Make You Rich?
- When Is the Best Time to Invest in Mutual Funds?
Receive News & Ratings for Life Science REIT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Life Science REIT and related companies with MarketBeat.com's FREE daily email newsletter.